Sandoz Raises CHF 550 Million in Bonds and Extends USD 2 Billion Credit Line

An update from Sandoz Group Ltd ( (CH:SDZ) ) is now available.

Sandoz has raised CHF 550 million through a dual-tranche Swiss franc bond issuance, comprising six-year and ten-year notes, to fund general corporate purposes and refinance maturing debt. At the same time, the company extended the maturity of its unutilized USD 2 billion multi-currency revolving credit facility by one year to March 2031, reinforcing its liquidity position.

Management said these financing moves will strengthen the balance sheet, keep the average interest rate on gross debt below 4%, and extend the group’s debt-maturity profile out to 2036. Sandoz, which is supported by a major international bank syndicate and aims to preserve its investment-grade ratings from Moody’s and S&P, is targeting an average debt tenor of six to seven years to underpin its long-term growth strategy in affordable medicines.

The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF71.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.

More about Sandoz Group Ltd

Sandoz Group AG, headquartered in Basel, Switzerland, is a global leader in affordable medicines with a portfolio of about 1,300 products spanning treatments from common illnesses to cancer. The company focuses on pioneering patient access through generics and biosimilars, employing more than 20,000 people worldwide and reaching over one billion patients annually, while generating significant healthcare savings.

Average Trading Volume: 796,238

Technical Sentiment Signal: Buy

Current Market Cap: CHF27.9B

Learn more about SDZ stock on TipRanks’ Stock Analysis page.